Goldman Sachs Forecats Q2 GDP Crashing 34% in US w/ 15% Unemployment

This morning Goldman Sachs released a new forecast for Q3 US GDP and showing a 34% annualized decline and reaching 15% unemployment. The new outlook shows a deeper recession than the previous report last week which predicted 9 percent unemployment and a 24 percent decline in Q2 GDP.

Goldman sees the virus causing an economic impact of around -13% in the month of April with the hospitality industry being his the hardest:

At the moment they see a strong recovery in the second half of the year; with some decline a result of the “second-round income effects”:

Goldman estimates slightly more than half the near-term output decline is made up by year-end with real GDP falling 6.2% in 2020 on an annual-average basis. In Q3, they see a “V-shape” recovery, with a a bigger bounce of 19 percent making up for lost production.


Information for this briefing was found via Goldman Sachs. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Uranium Is Back On America’s Radar | Corey Dias –  Anfield Energy

The Russell Will Lead the Next Market Crash!? | John Feneck

The Global Conflict Has Already Started | Bryan Cunningham

Recommended

ESGold Secures $9 Million In Non-Dilutive Funding From Ocean Partners

Altamira Gold Encounters Porphyritic Intrusive Rocks In Initial Scout Drilling At Regional Targets

Related News

Canada’s Labour Market Gains Slowing Down as Unemployment Rate Declines by 0.7% in August

It appears that Canada’s labour market continues to rebound from its coronavirus-induced historic slump of...

Friday, September 4, 2020, 03:41:37 PM

UK Economy Contracts by Most on Record, GDP Down by 20.1% in Q2

It appears that the UK has bogged down after spinning its tires endlessly in the...

Wednesday, August 12, 2020, 11:46:47 AM

Revive Expects To Complete Phase 3 Interim Analysis In December On Bucillamine In Treatment of COVID-19

Revive Therapeutics (CSE: RVV) provided an update on the status of its ongoing phase three...

Monday, October 26, 2020, 10:54:38 AM

Revive Therapeutics Granted FDA Approval For Phase 3 Clinical Trial For Bucillamine In COVID-19 Treatment

It’s a big day for Revive Therapeutics (CSE: RVV) (OTC: RVVTF). The company announced this...

Friday, July 31, 2020, 09:16:29 AM

Federal Tax Receipts Fall Three Times Greater Than Reported Unemployment Numbers, Suggestive of Employment Data Inaccuracy

Amid the unprecedented onset of the coronavirus pandemic, many Americans suddenly found themselves under mandatory...

Tuesday, June 16, 2020, 03:56:00 PM